EVOBRUTINIB TREATMENT REDUCES THE DAMAGE TO THE CNS AND INCREASES THE NUMBER OF CLASSICAL DENDRITIC CELLS IN EXPERIMENTAL MULTIPLE SCLEROSIS

EVOBRUTINIB TREATMENT REDUCES THE DAMAGE TO THE CNS AND INCREASES THE NUMBER OF CLASSICAL DENDRITIC CELLS IN EXPERIMENTAL MULTIPLE SCLEROSIS

Bibliographic Details
Main Authors:	Mari Paz Serrano-Regal, Leticia Calahorra, Inmaculada Alonso-García, Ursula Boschert, Philipp Haselmayer, María Cristina Ortega, Isabel Machin-Diaz, Celia Camacho-Toledano, Jennifer García-Arocha, Diego Clemente
Format:	Article
Language:	English
Published:	Elsevier 2023-10-01
Series:	IBRO Neuroscience Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2667242123005353

Similar Items

CIRCULATING MYELOID-DERIVED SUPPRESSOR CELLS AS A POTENTIAL BIOINDICATOR OF THE ENDOGENOUS MYELIN REPAIR CAPACITY IN EXPERIMENTAL MULTIPLE SCLEROSIS
by: Mari Paz Serrano-Regal, et al.
Published: (2023-10-01)

Regulatory Cells in Multiple Sclerosis: From Blood to Brain
by: Leticia Calahorra, et al.
Published: (2022-02-01)

Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib
by: Liza Rijvers, et al.
Published: (2022-08-01)

Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants
by: Orestis Papasouliotis, et al.
Published: (2022-12-01)

MYELOID-DERIVED SUPPRESSOR CELL BURDEN IN THE CNS AND BLOOD IS ASSOCIATED WITH DISEASE SEVERITY OF MULTIPLE SCLEROSIS PATIENTS
by: María Cristina Ortega, et al.
Published: (2023-10-01)

Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration‐QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers
by: Andreas Becker, et al.
Published: (2020-03-01)

Determination of a clinically effective evobrutinib dose: Exposure–response analyses of a phase II relapsing multiple sclerosis study
by: Orestis Papasouliotis, et al.
Published: (2022-12-01)

Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis
by: Celia Camacho-Toledano, et al.
Published: (2022-11-01)

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Dose‐Ranging Trial
by: Daniel J. Wallace, et al.
Published: (2023-01-01)

FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
by: Jun Yan, et al.
Published: (2019-01-01)

Case report: A case of classic hairy cell leukemia with CNS involvement treated with vemurafenib
by: Anna E. Johnson, et al.
Published: (2023-01-01)

CNS and CNS diseases in relation to their immune system
by: Jianhao Xu, et al.
Published: (2022-11-01)

Author Correction: FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
by: Jun Yan, et al.
Published: (2019-02-01)

Multiple CNS Tumors in a Patient With Neurofibromatosis Type 2: Classical Presentation of a Rare Diseas
by: Aamer Ubaid, et al.
Published: (2020-10-01)

Macrophages and dendritic cells as actors in the immune reaction of classical Hodgkin lymphoma.
by: Christiane Silke Tudor, et al.
Published: (2014-01-01)

Human CNS cultures exposed to HIV-1 gp120 reproduce dendritic injuries of HIV-1-associated dementia
by: Hammond Robert R, et al.
Published: (2004-05-01)

Reflections on Cerebellar Neuropathology in Classical Scrapie
by: Adolfo Toledano-Díaz, et al.
Published: (2021-04-01)

Flavonoids and the CNS
by: Anna K. Jäger, et al.
Published: (2011-02-01)

Exploring the Immunomodulatory Moonlighting Activities of Acute Phase Proteins for Tolerogenic Dendritic Cell Generation
by: Inmaculada Serrano, et al.
Published: (2018-04-01)

Discrepancy in Response of Mouse Dendritic Cells against BCG: Weak Immune Effects of Plasmacytoid Dendritic Cells Compared to Classical Dendritic Cells despite the Uptake of Bacilli
by: Chuang Meng, et al.
Published: (2023-02-01)

Negative campaigning among coalition partners
by: Martin Haselmayer, et al.
Published: (2018-09-01)

1,25-dihydroxyvitamin D3 conditioned CD11c+ dendritic cells are effective initiators of CNS autoimmune disease
by: Dario eBesusso, et al.
Published: (2015-11-01)

The Dendritic Cell Response to Classic, Emerging, and Homeostatic Danger Signals. Implications for Autoimmunity.
by: Paul Matthew Gallo, et al.
Published: (2013-06-01)

Treatment and long-term follow-up of primary CNS classical Hodgkin's lymphoma – A case report and review of the literature
by: Paul A. Szelemej, et al.
Published: (2017-09-01)

Fatty Acid Synthesis in Glial Cells of the CNS
by: Aida V. Garcia Corrales, et al.
Published: (2021-07-01)

Pericyte derivation and transplantation for blood-CNS barrier reconstitution in CNS disorders
by: Hyun Woo Kim, et al.
Published: (2024-06-01)

Transcriptional and epigenomic landscapes of CNS and non-CNS vascular endothelial cells
by: Mark F Sabbagh, et al.
Published: (2018-09-01)

The Role of Peripheral CNS‐Directed Antibodies in Promoting Inflammatory CNS Demyelination
by: Silke Kinzel, et al.
Published: (2017-06-01)

Fate mapping of dendritic cells
by: Barbara Ursula Schraml, et al.
Published: (2015-05-01)

Primary CNS lymphoma.
by: Losseff, N, et al.
Published: (1993)

Meningiomas with CNS invasion
by: Konstantinos Gousias, et al.
Published: (2023-06-01)

CNS Diseases and Uveitis
by: Pia Allegri, et al.
Published: (2011-01-01)

Primary CNS Teratocarcinoma
by: Danilo eVitorovic, et al.
Published: (2012-02-01)

CNS infections in childhood
by: Arushi Gahlot Saini, et al.
Published: (2015-01-01)

Interleukin 18 in the CNS
by: Sugama Shuei, et al.
Published: (2010-01-01)

CNS Malformations in the Newborn
by: Kristin Barañano, et al.
Published: (2022-01-01)

Molecular identification of CNS NB-FOXR2, CNS EFT-CIC, CNS HGNET-MN1 and CNS HGNET-BCOR pediatric brain tumors using tumor-specific signature genes
by: Maria Łastowska, et al.
Published: (2020-07-01)

Energy based mechano-electrophysiological model of CNS damage at the tissue scale
by: Garcia-Gonzalez, D, et al.
Published: (2018)

CAR T-Cells for CNS Lymphoma: Driving into New Terrain?
by: Philipp Karschnia, et al.
Published: (2021-05-01)

Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation
by: Andrey Korshunov, et al.
Published: (2021-02-01)